Patients who are MRDneg demonstrated a survival advantage compared with patients who are MRDpos in the ALL06 genomic study cohort. Kaplan-Meier curves assessed OS and RFS for (A-B) genomic study cohort (57 patients), (C-D) patients with T-ALL (17 patients) vs B-ALL (40 patients), (E-F) patients who were MRDneg vs MRDpos at TP1 (day 33), (G-H) patients who were MRDneg vs MRDpos at TP2 day 79). Bold lines represent percentage survival, and dotted lines represent 95% CI. Statistical significance was determined by the log-rank survival (Mantel-Cox) test.